shutterstock_1486264271_jhvephoto
JHVEphoto / Shutterstock.com
20 July 2021Big PharmaAlex Baldwin

PTAB invalidates Medytox Botox patent

The Patent Trial and Appeal Board (PTAB) has ruled that a Medytox patent for its wrinkle treatment should not have been granted.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
20 April 2015   An Ontario-based company has sued Allergan for allegedly infringing a method patent that protects the use of cosmetic drug Botox to treat back pain.
article
3 May 2022   The US International Trade Commission has agreed to investigate imports of botulinum toxin products following a complaint that they infringe trade secrets.
Big Pharma
29 June 2023   Board did not violate procedure regarding ‘preliminary guidance’ say Federal Circuit judges | Medytox’s substitute claims found to be ‘unpatentable’.

More on this story

Americas
20 April 2015   An Ontario-based company has sued Allergan for allegedly infringing a method patent that protects the use of cosmetic drug Botox to treat back pain.
article
3 May 2022   The US International Trade Commission has agreed to investigate imports of botulinum toxin products following a complaint that they infringe trade secrets.
Big Pharma
29 June 2023   Board did not violate procedure regarding ‘preliminary guidance’ say Federal Circuit judges | Medytox’s substitute claims found to be ‘unpatentable’.

More on this story

Americas
20 April 2015   An Ontario-based company has sued Allergan for allegedly infringing a method patent that protects the use of cosmetic drug Botox to treat back pain.
article
3 May 2022   The US International Trade Commission has agreed to investigate imports of botulinum toxin products following a complaint that they infringe trade secrets.
Big Pharma
29 June 2023   Board did not violate procedure regarding ‘preliminary guidance’ say Federal Circuit judges | Medytox’s substitute claims found to be ‘unpatentable’.